Aug. 31 at 5:04 PM
$ACAD
Q2 2026: revenue
$307.96M, net income
$31.5M. DAYBUE (Rett syndrome)
$125M in net sales; NUPLAZID (Parkinson's psychosis)
$183M. Raised FY26 revenue guidance to
$1.24B-
$1.30B.
Stock up ~11.9% in the month through Aug. 28, hit intramonth high of
$30.96 before consolidating near
$29. Watch patient starts, script trends, payer coverage, and remlifanserin pipeline data as the next catalysts.
$ACAD #Biotech #Pharma
https://prismmarketview.com/acadia-pharmaceuticals-builds-growth-momentum-as-daybue-and-nuplazid-sales-rise/
